When was Core Biogenesis founded?

Core Biogenesis was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Core Biogenesis located?

Core Biogenesis is headquartered in Paris, France.

Who is the current CEO of Core Biogenesis?

Alexandre Reeber of Core Biogenesis. They have also founded 1 company.

How many employees does Core Biogenesis have?

As of Aug 31, 2026, the latest employee count at Core Biogenesis is 31.

Is Core Biogenesis a funded company?

Core Biogenesis is a funded company, having raised a total of $14.1M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 08, 2020.

When was the latest funding round of Core Biogenesis?

Core Biogenesis' latest funding was a $***** Series A round on Mar 29, 2022, with participation from 4 investors. Its primary sector is Life Sciences Platforms and Tools. In France, the Life Sciences Platforms and Tools sector has seen $17M in funding in 2026 to date.

Where does Core Biogenesis rank among its competitors?

Core Biogenesis ranks 3rd amongst 93 active competitors, of which 19 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Qkine, which secured $2.03M in Sep, 2026.

Who are the top competitors of Core Biogenesis?

Core Biogenesis' top competitors include Qkine, Laigo Biotechnology and Future Fields. Among them, Qkine secured the most recent funding round in September, 2026.

Core Biogenesis - 2026 Company Profile, Team, Funding, Competitors & Financials

Core Biogenesis is a series A company based in Paris (France), founded in 2020 by Maurice Moloney and Alexandre Reeber. It operates as a Provider of UBaaS platform for recombinant protein bioproduction. Core Biogenesis has raised $14.1M in funding from investors like Plug and Play Tech Center, Entrepreneurs First and XAnge. The company has 93 active competitors, including 19 funded and 5 that have exited. Its top competitors include companies like Qkine, Laigo Biotechnology and Future Fields.

Company Details

Provider of UBaaS platform for recombinant protein bioproduction. The company uses plants as biofactories to scale the production of high-value bioproducts that uses ultra-scalable bioproduction as a service (UBaaS) platform to accelerate mass production. The product of the company inlcude human growth factors.

Key Metrics

Founded Year

2020

Location

Paris, France

Stage

Series A

Total Funding

$14.1M in 3 rounds

Latest Funding Round

Series A, Mar 29, 2022, $*****

Investors

Plug and Play Tech Center & 7 more

Ranked

3^rd among 93 active competitors

Employee Count

31 as on Aug 31, 2026

Similar Companies

Qkine & 94 more

View Core Biogenesis' full profile

Core Biogenesis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
CORE BIOGENESIS CIN: 883231128 , France, Active	Apr 05, 2020	-	-	-

Core Biogenesis has raised a total funding of $14.1M over 3 rounds. Its first funding round was on Dec 08, 2020. Its latest funding round was a Series A round on Mar 29, 2022 for $*****. 4 investors participated in its latest round. Core Biogenesis has 8 institutional investors.

Here is the list of recent funding rounds of Core Biogenesis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 29, 2022	1166060	Series A	9998680	9992045	2932368	5044912
Mar 23, 2022	6729273	Grant (prize money)	2433980	2827490	9435853	EIC Fund
Dec 08, 2020	2606906	Seed	6276218	3830107	Entrepreneurs First & 1 more	XAnge

Access funding benchmarks and valuations. Sign up today!

View details of Core Biogenesis's funding rounds and investors

The founders of Core Biogenesis are Maurice Moloney and Alexandre Reeber. Alexandre Reeber is the CEO of Core Biogenesis.

Here are the details of Core Biogenesis' key team members:

Maurice Moloney: Co-Founder & Advisor of Core Biogenesis.
Alexandre Reeber: Co-Founder & CEO of Core Biogenesis.
Contact Info: 1 email address

View details of Core Biogenesis's Founder profiles and Board Members

Core Biogenesis' employee count trend

Core Biogenesis has 31 employees as of Aug 26. Here is Core Biogenesis's employee count trend over the years:

Employee count trend for Core Biogenesis

Uncover Core Biogenesis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Core Biogenesis include Qkine, Laigo Biotechnology and Future Fields. Here is the list of Top 10 competitors of Core Biogenesis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Qkine 2016, Cambridge (United Kingdom), Series A	Developer of animal-free growth factors for life science applications	$10.2M	Parkwalk, Downing Ventures & 21 others	61/100
2nd	Laigo Biotechnology 2023, Utrecht (Netherlands), Seed	Developer of targeted protein degradation technology for therapeutic applications	$19.8M	Kurma Partners, Curie Capital & 8 others	53/100
3rd	Core Biogenesis 2020, Paris (France), Series A	Provider of UBaaS platform for recombinant protein bioproduction	$14.1M	By The Tower, EIC Fund & 6 others	47/100
4th	Future Fields 2017, Edmonton (Canada), Series A	Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins	$21.6M	Bee Partners, Toyota Ventures & 21 others	43/100
5th	Orf Genetics 2001, Kopavogur (Iceland), Series A	Developer of recombinant protein technology	$5.87M	EIC Fund, Europa	43/100
6th	KAICO 2018, Fukuoka (Japan), Series B	Manufacturer of portfolio of proteins and other biological cytokines and enzymes	$8.15M	ITOCHU Technology Ventures, Tokyo Century ... & 8 others	38/100
7th	Xias Bio 2020, United States, Seed	Developer of recombinant proteins	$5.23M	IndieBio, SOSV & 4 others	38/100
8th	MarraBio 2011, Newcastle Upon Tyne (United Kingdom), Seed	Biotechnology research company that provides bacterial protein polymers	-	Maven Capital Partners, Northstar Ventures ... & 2 others	38/100
9th	Hunan Zhongsheng Quanpeptide Biotechnology 2017, Zhuzhou (China), Series B	Developer of peptide discovery technology, peptide libraries, and related research products	$47.9M	CDH, Xjsci & 7 others	37/100
10th	Algenex 2005, Madrid (Spain), Series B	Developer of recombinant biologics for animal and human health	$13.3M	Columbus Venture Partners, Vita Advisory & 1 others	35/100